Literature DB >> 34099640

The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.

Henry Nording1,2, Lasse Baron1, David Haberthür3, Frederic Emschermann4, Matthias Mezger1, Manuela Sauter1, Reinhard Sauter1, Johannes Patzelt5, Kai Knoepp6, Anne Nording7, Moritz Meusel5, Roza Meyer-Saraei2,5, Ruslan Hlushchuk3, Daniel Sedding6, Oliver Borst4, Ingo Eitel2,5, Christian M Karsten8, Robert Feil9, Bernd Pichler10, Jeanette Erdmann2,11, Admar Verschoor8, Emmanouil Chavakis12, Triantafyllos Chavakis13, Philipp von Hundelshausen14, Jörg Köhl8,15, Meinrad Gawaz4, Harald F Langer16,17,18.   

Abstract

Platelets contribute to the regulation of tissue neovascularization, although the specific factors underlying this function are unknown. Here, we identified the complement anaphylatoxin C5a-mediated activation of C5a receptor 1 (C5aR1) on platelets as a negative regulatory mechanism of vessel formation. We showed that platelets expressing C5aR1 exert an inhibitory effect on endothelial cell functions such as migration and 2D and 3D tube formation. Growth factor- and hypoxia-driven vascularization was markedly increased in C5ar1-/- mice. Platelet-specific deletion of C5aR1 resulted in a proangiogenic phenotype with increased collateralization, capillarization and improved pericyte coverage. Mechanistically, we found that C5a induced preferential release of CXC chemokine ligand 4 (CXCL4, PF4) from platelets as an important antiangiogenic paracrine effector molecule. Interfering with the C5aR1-CXCL4 axis reversed the antiangiogenic effect of platelets both in vitro and in vivo.In conclusion, we identified a mechanism for the control of tissue neovascularization through C5a/C5aR1 axis activation in platelets and subsequent induction of the antiangiogenic factor CXCL4.

Entities:  

Year:  2021        PMID: 34099640     DOI: 10.1038/s41467-021-23499-w

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  108 in total

1.  Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.

Authors:  Elizabeth B Staab; Sam D Sanderson; Sandra M Wells; Jill A Poole
Journal:  Int Immunopharmacol       Date:  2014-05-21       Impact factor: 4.932

Review 2.  Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments.

Authors:  Admar Verschoor; Christian M Karsten; Steven P Broadley; Yves Laumonnier; Jörg Köhl
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

3.  Immunology. The new view of complement.

Authors:  Mitch Leslie
Journal:  Science       Date:  2012-08-31       Impact factor: 47.728

4.  The effect of C1 inhibitor on myocardial ischemia and reperfusion injury.

Authors:  Fengxin Lu; Stacey M Fernandes; Alvin E Davis
Journal:  Cardiovasc Pathol       Date:  2012-06-16       Impact factor: 2.185

5.  Myocardial infarction induces atrial inflammation that can be prevented by C1-esterase inhibitor.

Authors:  Mark Pv Begieneman; Reindert W Emmens; Liza Rijvers; Linde Woudstra; Walter J Paulus; Bela Kubat; Alexander Ba Vonk; Albert C van Rossum; Diana Wouters; Sacha Zeerleder; Marieke van Ham; Casper G Schalkwijk; Hans Wm Niessen; Paul Aj Krijnen
Journal:  J Clin Pathol       Date:  2016-05-06       Impact factor: 3.411

6.  Drusen complement components C3a and C5a promote choroidal neovascularization.

Authors:  Miho Nozaki; Brian J Raisler; Eiji Sakurai; J Vidya Sarma; Scott R Barnum; John D Lambris; Yali Chen; Kang Zhang; Balamurali K Ambati; Judit Z Baffi; Jayakrishna Ambati
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-01       Impact factor: 11.205

Review 7.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

8.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.

Authors:  Guillermina Girardi; Dmitry Yarilin; Joshua M Thurman; V Michael Holers; Jane E Salmon
Journal:  J Exp Med       Date:  2006-08-21       Impact factor: 14.307

Review 9.  Complement--tapping into new sites and effector systems.

Authors:  Martin Kolev; Gaelle Le Friec; Claudia Kemper
Journal:  Nat Rev Immunol       Date:  2014-11-14       Impact factor: 53.106

Review 10.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

View more
  5 in total

Review 1.  Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity.

Authors:  Milka Koupenova; Alison C Livada; Craig N Morrell
Journal:  Circ Res       Date:  2022-01-20       Impact factor: 17.367

Review 2.  Neutrophils-From Bone Marrow to First-Line Defense of the Innate Immune System.

Authors:  Richard Felix Kraus; Michael Andreas Gruber
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

Review 3.  Targeting Cell-Specific Molecular Mechanisms of Innate Immunity in Atherosclerosis.

Authors:  M Sauter; H F Langer
Journal:  Front Physiol       Date:  2022-04-01       Impact factor: 4.755

4.  Cobra Venom Factor Boosts Arteriogenesis in Mice.

Authors:  Philipp Götz; Sharon O Azubuike-Osu; Anna Braumandl; Christoph Arnholdt; Matthias Kübler; Lisa Richter; Manuel Lasch; Lisa Bobrowski; Klaus T Preissner; Elisabeth Deindl
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

5.  Platelet depletion does not alter long-term functional outcome after cerebral ischaemia in mice.

Authors:  Rebecca D Steubing; Fabian Szepanowski; Christina David; Ayan Mohamud Yusuf; Stine Mencl; Anne-Kathrin Mausberg; Harald F Langer; Manuela Sauter; Cornelius Deuschl; Michael Forsting; Anke C Fender; Dirk M Hermann; Ana I Casas; Friederike Langhauser; Christoph Kleinschnitz
Journal:  Brain Behav Immun Health       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.